Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 11;14(14):3367. doi: 10.3390/cancers14143367

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Patients with TERT promoter ctDNA have significantly shorter OS than those without. Total 85 u-HCC patients treated with Atezo/Bev were classified into two groups according to the presence or absence of specific ctDNA mutations including TERT (A,D), TP53 (B,E), CTNNB1 (C,F). The Kaplan–Meier curves of progression-free survival (PFS) (A–C) and overall survival (OS) (D–F) for each group. ctDNA, circulating tumor DNA; u-HCC, unresectable hepatocellular carcinoma; Atezo/Bev, Atezolizumab and bevacizumab.